21 results
8-K
EX-99.1
LGVN
Longeveron Inc - Ordinary Shares
20 Jul 23
Longeveron Appoints Lisa Locklear as Chief Financial Officer
8:30am
will be vital as we continue advancing our innovative cellular therapy assets toward important milestones,” said Wa’el Hashad, Longeveron CEO. “We are excited
DEF 14A
LGVN
Longeveron Inc - Ordinary Shares
13 May 22
Definitive proxy
4:10pm
: SNGX)), VP of Business Development & Operations at Heart Genomics, and Director of Clinical Affairs at Innovative Drug Delivery Systems. Early in his
424B3
ykwsv uphzahyally0h
22 Dec 21
Prospectus supplement
5:07pm
10-K
ie50w dbn1g32r9y
30 Mar 21
Annual report
4:51pm
424B4
9a2o7 87s
12 Feb 21
Prospectus supplement with pricing info
4:09pm
S-1
EX-10.10
z4fv3mpu3u2hcbdn1ny
19 Jan 21
IPO registration
5:21pm
S-1
6b3u6700
19 Jan 21
IPO registration
5:21pm
S-1
EX-10.9
9gfan72 9drbn
19 Jan 21
IPO registration
5:21pm
S-1
EX-10.8
39soysvgfe7yt 65pt
19 Jan 21
IPO registration
5:21pm
DRS/A
EX-10.10
vzv25va
30 Dec 20
Draft registration statement (amended)
12:00am
DRS/A
1oh5ua1
30 Dec 20
Draft registration statement (amended)
12:00am
DRS/A
EX-10.9
e7ya6o0
30 Dec 20
Draft registration statement (amended)
12:00am
DRS/A
EX-10.8
denbonrekkr5z
30 Dec 20
Draft registration statement (amended)
12:00am